PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 8832768-7 1996 Basal and DMI-induced GH levels, on the other hand, did not differ in PTSD versus normal subjects. Desipramine 10-13 growth hormone 1 Homo sapiens 22-24 9595891-18 1998 DISCUSSION: Treatment with either desipramine or ECT modified noradrenergic functioning in patients with depression, as assessed by growth hormone response to the clonidine challenge. Desipramine 34-45 growth hormone 1 Homo sapiens 132-146 2095944-0 1990 Responses of growth hormone to desipramine in endogenous and non-endogenous depression. Desipramine 31-42 growth hormone 1 Homo sapiens 13-27 1336635-0 1992 The desipramine-induced growth hormone response and the dexamethasone suppression test in obsessive-compulsive disorder. Desipramine 4-15 growth hormone 1 Homo sapiens 24-38 1647142-1 1991 Seven drug-free patients with bipolar affective disorder, currently in a manic phase, underwent desipramine-induced growth hormone (GH) stimulation, as did seven healthy age- and sex-matched subjects. Desipramine 96-107 growth hormone 1 Homo sapiens 116-130 1912129-1 1991 Twelve patients with DSM-III-R major depressive illness were tested for growth hormone (GH) response to desipramine (DMI), a noradrenergic (NA) reuptake inhibitor. Desipramine 104-115 growth hormone 1 Homo sapiens 72-86 1912129-1 1991 Twelve patients with DSM-III-R major depressive illness were tested for growth hormone (GH) response to desipramine (DMI), a noradrenergic (NA) reuptake inhibitor. Desipramine 104-115 growth hormone 1 Homo sapiens 88-90 1912129-1 1991 Twelve patients with DSM-III-R major depressive illness were tested for growth hormone (GH) response to desipramine (DMI), a noradrenergic (NA) reuptake inhibitor. Desipramine 117-120 growth hormone 1 Homo sapiens 72-86 1912129-1 1991 Twelve patients with DSM-III-R major depressive illness were tested for growth hormone (GH) response to desipramine (DMI), a noradrenergic (NA) reuptake inhibitor. Desipramine 117-120 growth hormone 1 Homo sapiens 88-90 1912129-6 1991 Patients treated with fluoxetine showed a significant decrease in DMI-mediated GH release irrespective of therapeutic outcome. Desipramine 66-69 growth hormone 1 Homo sapiens 79-81 2162547-1 1990 The growth hormone (GH) response to desipramine was measured in ten patients meeting criteria for post-stroke depression (PSD), eight age-matched post-stroke (PS) non-depressed patients and eight healthy controls. Desipramine 36-47 growth hormone 1 Homo sapiens 4-18 2162547-1 1990 The growth hormone (GH) response to desipramine was measured in ten patients meeting criteria for post-stroke depression (PSD), eight age-matched post-stroke (PS) non-depressed patients and eight healthy controls. Desipramine 36-47 growth hormone 1 Homo sapiens 20-22 2095944-1 1990 Desipramine, a monoamine reuptake inhibitor, was used to stimulate release of growth hormone (GH) in 29 DSM-III major depressives and in 10 healthy controls. Desipramine 0-11 growth hormone 1 Homo sapiens 78-92 2101962-0 1990 Influence of clenbuterol, a beta-adrenergic agonist, on desipramine induced growth hormone, prolactin and cortisol stimulation. Desipramine 56-67 growth hormone 1 Homo sapiens 76-90 2172531-1 1990 Desipramine, the monoamine reuptake inhibitor, acts predominantly on noradrenergic neurones, and via alpha-2 receptors brings about the release of growth hormone in normal healthy subjects. Desipramine 0-11 growth hormone 1 Homo sapiens 147-161 2101962-1 1990 We report herein the effects of the beta-adrenergic agonist clenbuterol on desipramine (DMI)-induced growth hormone (GH), prolactin (PRL) and cortisol secretion in healthy male subjects. Desipramine 75-86 growth hormone 1 Homo sapiens 101-115 2101962-1 1990 We report herein the effects of the beta-adrenergic agonist clenbuterol on desipramine (DMI)-induced growth hormone (GH), prolactin (PRL) and cortisol secretion in healthy male subjects. Desipramine 88-91 growth hormone 1 Homo sapiens 101-115 582390-0 1978 [Influence of single and repeated administration of desipramine (DMI) on the secretion of growth hormone (GH) (author"s transl)]. Desipramine 52-63 growth hormone 1 Homo sapiens 90-104 2975304-0 1988 Growth hormone response to desmethylimipramine in depressed and suicidal adolescents. Desipramine 27-46 growth hormone 1 Homo sapiens 0-14 4092710-0 1985 Growth hormone release after desipramine in depressive illness. Desipramine 29-40 growth hormone 1 Homo sapiens 0-14 4092710-2 1985 administration of 75 mg of desipramine on growth hormone (GH) secretion was investigated in a sample of 87 patients with major depressive disorders and in 31 normal controls. Desipramine 27-38 growth hormone 1 Homo sapiens 42-56 4092710-2 1985 administration of 75 mg of desipramine on growth hormone (GH) secretion was investigated in a sample of 87 patients with major depressive disorders and in 31 normal controls. Desipramine 27-38 growth hormone 1 Homo sapiens 58-60 6420832-1 1984 In order to compare the effects of chlorimipramine (CI) and desimipramine (DMI) on growth hormone (GH) and on prolactin (PRL) secretion equal doses of 25 mg CI or DMI were administered i.v. Desipramine 75-78 growth hormone 1 Homo sapiens 83-97 7178370-0 1982 Comparison of growth hormone stimulation induced by desimipramine, diazepam and metaclazepam in man. Desipramine 52-65 growth hormone 1 Homo sapiens 14-28 2615927-3 1989 The main findings were (1) sex differences in the growth hormone and cortisol response to desipramine and (2) a significant genetic component of the prolactin and cortisol response to desipramine as indicated by significantly (p less than 0.05) lower within-pair than between-pair variance in the sibling pairs but not random pairs of the experimental subjects. Desipramine 90-101 growth hormone 1 Homo sapiens 50-64 2667015-0 1989 Desipramine increases circulating growth hormone in elderly depressed patients: a pilot study. Desipramine 0-11 growth hormone 1 Homo sapiens 34-48 3628616-3 1987 Clinical studies have suggested that sleep deprivation could potentiate the therapeutic effects of antidepressants, and there were reports on DMI stimulation of GH. Desipramine 142-145 growth hormone 1 Homo sapiens 161-163 3628616-5 1987 The GH levels increased substantially (8- to 10-fold) after DMI in both experimental conditions. Desipramine 60-63 growth hormone 1 Homo sapiens 4-6 3628616-6 1987 Sleep deprivation neither changed GH basal levels nor potentiated the DMI-induced GH increase. Desipramine 70-73 growth hormone 1 Homo sapiens 82-84 3028722-5 1986 The alpha 2-mediated growth hormone response to clonidine was increased after one week"s treatment with desipramine and then reduced during the second and third weeks of treatment. Desipramine 104-115 growth hormone 1 Homo sapiens 21-35 3031716-2 1986 In this report the effects of various receptor blockers on desimipramine (DMI)-induced growth hormone (GH) secretion in healthy male subjects are presented. Desipramine 59-72 growth hormone 1 Homo sapiens 87-101 3031716-2 1986 In this report the effects of various receptor blockers on desimipramine (DMI)-induced growth hormone (GH) secretion in healthy male subjects are presented. Desipramine 59-72 growth hormone 1 Homo sapiens 103-105 3031716-2 1986 In this report the effects of various receptor blockers on desimipramine (DMI)-induced growth hormone (GH) secretion in healthy male subjects are presented. Desipramine 74-77 growth hormone 1 Homo sapiens 87-101 3031716-2 1986 In this report the effects of various receptor blockers on desimipramine (DMI)-induced growth hormone (GH) secretion in healthy male subjects are presented. Desipramine 74-77 growth hormone 1 Homo sapiens 103-105 3031716-6 1986 DMI-induced GH stimulation was not significantly different after DMI i.v. Desipramine 0-3 growth hormone 1 Homo sapiens 12-14 3031716-10 1986 ), GH secretion was significantly increased by 25 mg DMI (p less than 0.05) and 50 mg DMI (incomplete block design, n = 18). Desipramine 53-56 growth hormone 1 Homo sapiens 3-5 3031716-10 1986 ), GH secretion was significantly increased by 25 mg DMI (p less than 0.05) and 50 mg DMI (incomplete block design, n = 18). Desipramine 86-89 growth hormone 1 Homo sapiens 3-5 3031716-11 1986 GH secretion was significantly lower (p less than 0.01) after DMI in combination with 60 mg phentolamine i.v. Desipramine 62-65 growth hormone 1 Homo sapiens 0-2 3031716-15 1986 The DMI-induced GH increase following DMI plus 1 mg prazosin p.o. Desipramine 4-7 growth hormone 1 Homo sapiens 16-18 3031716-15 1986 The DMI-induced GH increase following DMI plus 1 mg prazosin p.o. Desipramine 38-41 growth hormone 1 Homo sapiens 16-18 3031716-17 1986 The results indicate that the GH-stimulating effect of DMI is primarily related to the ability of DMI to inhibit noradrenaline (NA) reuptake. Desipramine 55-58 growth hormone 1 Homo sapiens 30-32 3031716-17 1986 The results indicate that the GH-stimulating effect of DMI is primarily related to the ability of DMI to inhibit noradrenaline (NA) reuptake. Desipramine 98-101 growth hormone 1 Homo sapiens 30-32 3031716-18 1986 Should serotonergic receptors be involved in the DMI-induced GH secretion at all, they transmit a positive stimulus. Desipramine 49-52 growth hormone 1 Homo sapiens 61-63 4001280-2 1985 In previous studies it was shown that the tricyclic antidepressant desimipramine (DMI) had different stimulatory effects on growth hormone (GH), prolactin (PRL), ACTH and cortisol secretion in healthy subjects, depending on the mode of administration. Desipramine 67-80 growth hormone 1 Homo sapiens 124-138 4001280-2 1985 In previous studies it was shown that the tricyclic antidepressant desimipramine (DMI) had different stimulatory effects on growth hormone (GH), prolactin (PRL), ACTH and cortisol secretion in healthy subjects, depending on the mode of administration. Desipramine 82-85 growth hormone 1 Homo sapiens 124-138 6087965-4 1984 By contrast, the growth hormone response to clonidine tended to be increased after one week of desipramine, reduced after three weeks of treatment, and further reduced after discontinuation. Desipramine 95-106 growth hormone 1 Homo sapiens 17-31 6735152-3 1984 Similarly inhibition of NE reuptake by imipramine or desmethylimipramine were followed by reduced GH secretion. Desipramine 53-72 growth hormone 1 Homo sapiens 98-100 6959166-1 1982 The effect of 4 to 6 weeks of treatment with the antidepressants, desmethylimipramine and amitriptyline, on the growth hormone response to clonidine was studied in 12 depressed patients. Desipramine 66-85 growth hormone 1 Homo sapiens 112-126 582390-0 1978 [Influence of single and repeated administration of desipramine (DMI) on the secretion of growth hormone (GH) (author"s transl)]. Desipramine 52-63 growth hormone 1 Homo sapiens 106-108 582390-0 1978 [Influence of single and repeated administration of desipramine (DMI) on the secretion of growth hormone (GH) (author"s transl)]. Desipramine 65-68 growth hormone 1 Homo sapiens 90-104 582390-0 1978 [Influence of single and repeated administration of desipramine (DMI) on the secretion of growth hormone (GH) (author"s transl)]. Desipramine 65-68 growth hormone 1 Homo sapiens 106-108 582390-1 1978 DMI leads to stimulation of GH in healthy male subjects 60--120 min after i.m. Desipramine 0-3 growth hormone 1 Homo sapiens 28-30 582390-3 1978 During a 20-day administration of 2 x 75 mg DMI per day a repeated stimulation of GH was provable on days 0, 10 and 20 in two male patients, whereas no stimulation of GH occurred in two female patients who underwent the same treatment. Desipramine 44-47 growth hormone 1 Homo sapiens 82-84